The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The Impact of Diabetes and Diabetes Medications on Bone Health
Abstract
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures despite increased body weight and normal or higher bone mineral density. The mechanisms by which T2DM increases skeletal fragility are unclear. It is likely that a combination of factors, including a greater risk of falling, regional osteopenia, and impaired bone quality, contributes to the increased fracture risk. Drugs for the treatment of T2DM may also impact on the risk for fractures. For example, thiazolidinediones accelerate bone loss and increase the risk of fractures, particularly in older women. In contrast, metformin and sulfonylureas do not appear to have a negative effect on bone health and may, in fact, protect against fragility fracture. Animal models indicate a potential role for incretin hormones in bone metabolism, but there are only limited data on the impact of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists on bone health in humans. Animal models also have demonstrated a role for amylin in bone metabolism, but clinical trials in patients with type 1 diabetes with an amylin analog (pramlintide) have not shown a significant impact on bone metabolism. The effects of insulin treatment on fracture risk are inconsistent with some studies showing an increased risk and others showing no effect. Finally, although there is limited information on the latest class of medications for the treatment of T2DM, the sodium-glucose co-transporter-2 inhibitors, these drugs do not seem to increase fracture risk. Because diabetes is an increasingly common chronic condition that can affect patients for many decades, further research into the effects of agents for the treatment of T2DM on bone metabolism is warranted. In this review, the physiological mechanisms and clinical impact of diabetes treatments on bone health and fracture risk in patients with T2DM are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Although the exact mechanism is not fully understood, metformin likely improves glucose metabolism via activation of AMP-activated protein kinase (AMPK) (Figure 2) (64, 65).”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Endocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554 · cited 1×
“(48) demonstrated that the relatively strong effects of loss”
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 1×
“Although the exact mechanism is not fully understood, metformin likely improves glucose metabolism via activation of AMP-activated protein kinase (AMPK) (Figure 2) (64, 65).”
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Newman, A. B., Haggerty, C. L., Goodpaster, B., Harris, T., Kritchevsky, S., Nevitt, M., Miles, T. P., Visser, M., & The Health, A. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51105.x · Cited by 505
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426
Ferron, M., McKee, M. D., Levine, R. L., Ducy, P., & Karsenty, G. (2012) · Bone · doi:10.1016/j.bone.2011.04.017 · Cited by 414 · cited 1×
“al (49) found that intermittent administration of osteo-”
Fukumoto, S., & Martin, T. J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.02.001 · Cited by 311
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312135 · Cited by 206 · cited 1×
“ficiency has been shown to lead to bone loss in mice, and treatment with amylin can partially reverse osteopenia in ovariectomized rats (127, 128).”
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
Cornish, J., Callon, K. E., Bava, U., Kamona, S. A., Cooper, G. J. S., & Reid, I. R. (2001) · Bone · doi:10.1016/s8756-3282(01)00494-x · Cited by 173
Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156
Guntur, A. R., & Rosen, C. J. (2012) · Endocrine Practice · doi:10.4158/ep12141.ra · Cited by 150
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Amylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice
Cornish, J., Callon, K. E., Cooper, G. J. S., & Reid, I. R. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1163 · Cited by 126
Cornish, J., Callon, K. E., King, A. R., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e694 · Cited by 102
Amylin inhibits ovariectomy-induced bone loss in rats
Horcajada-Molteni, M., Davicco, M., Lebecque, P., Coxam, V, Young, A., & Barlet, J. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650663 · Cited by 40 · cited 1×
“ficiency has been shown to lead to bone loss in mice, and treatment with amylin can partially reverse osteopenia in ovariectomized rats (127, 128).”
Systemic administration of a novel octapeptide, amylin-(1—8), increases bone volume in male mice
Cornish, J., Callon, K. E., Gasser, J. A., Bava, U., Gardiner, E. M., Coy, D. H., Cooper, G. J. S., & Reid, I. R. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.4.e730 · Cited by 38
Pietschmann, P., Farsoudi, K. H., Hoffmann, O., Klaushofer, K., Hörandner, H., & Peterlik, M. (1993) · Bone · doi:10.1016/8756-3282(93)90244-5 · Cited by 28
Cited by
Hygum, K., Starup-Linde, J., Harsløf, T., Vestergaard, P., & Langdahl, B. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0652 · Cited by 320
The role of autophagy in bone metabolism and clinical significance
Wang, J., Zhang, Y., Cao, J., Wang, Y., Anwar, N., Zhang, Z., Zhang, D., Ma, Y., Xiao, Y., Xiao, L., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2186112 · Cited by 320
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
The impact of type 2 diabetes on bone metabolism
Sanches, C. P., Vianna, A. G. D., & Barreto, F. D. C. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0278-1 · Cited by 115
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
Metadata
- Authors
- Gilbert, M. P., & Pratley, R. E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-03-04
- Volume
- 36
- Issue
- 2
- Pages
- 194-213
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2112704642
- Cited by
- 209
- References
- 37
- FWCI
- 19.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.